SCHEMBL2905586

SCHEMBL2905586

COc1ccc(C(N)=O)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.64
TUBB4A P04350 2/20 0.60
TUBB P07437 2/20 0.60
TUBA3C P0DPH7 2/20 0.60
TUBA1B P68363 2/20 0.60
TUBA4A P68366 2/20 0.60
TUBB4B P68371 2/20 0.60
TUBB3 Q13509 2/20 0.60
TUBB2A Q13885 2/20 0.60
TUBB8 Q3ZCM7 2/20 0.60
TUBA3E Q6PEY2 2/20 0.60
TUBA1A Q71U36 2/20 0.60
TUBA1C Q9BQE3 2/20 0.60
TUBB6 Q9BUF5 2/20 0.60
TUBB2B Q9BVA1 2/20 0.60
TUBB1 Q9H4B7 2/20 0.60
MAPK1 P28482 1/20 0.60
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL19205254 0.93 RECQL (0.57) RECQLTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL335681 0.86 MAPK1 (0.77) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL29415167 0.86 MAPK1 (0.77) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL340398 0.85 MEN1 (0.72) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL29428890 0.85 MEN1 (0.72) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL28575503 0.85 TUBB4A (0.60) RECQLTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL27575811 0.84 TUBB4A (0.80) RECQLTUBB4ATUBBTUBA3CTUBA1B
Hydrochloric Acid SCHEMBL5154533 0.84 MAPK1 (0.74) MAPK1CYP1A2CYP3A4CYP2C9TSHR
Hydrochloric Acid SCHEMBL8337978 0.83 MEN1 (0.70) MAPK1CYP1A2CYP3A4CYP2C9TSHR
Isovanillic Acid SCHEMBL180473 0.82 HTT (0.72) RECQLTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP claimed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US claimed
EP-1635821-B1 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARM INC (US) 2009-07-08 EP claimed
US-20070123531-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. 2007-05-31 US claimed
EP-1635821-A2 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES Elan Pharmaceuticals, Inc. (US) 2006-03-22 EP claimed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US claimed
US-20050032868-A1 Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. 2005-02-10 US claimed
WO-2004099155-A2 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 WO claimed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP claimed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US claimed
US-20030199553-A1 Antidiabetic agents GAMMILL RONALD B (US) 2003-10-23 US claimed
WO-2003072570-A1 ANTIDIABETIC AGENTS PFIZER PRODUCTS INC. (US) 2003-09-04 WO claimed
EP-1340500-A1 Antidiabetic agents Pfizer Products Inc. (US) 2003-09-03 EP claimed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO claimed
WO-1986006628-A1 BENZAMIDE AND NICOTINAMIDE RADIOSENSITIZERS SRI INTERNATIONAL (US) 1986-11-20 WO claimed
US-20260027090-A1 Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity VTV THERAPEUTICS LLC (US) 2026-01-29 US disclosed
US-20250195671-A1 COVALENT ANESTHETIC-POLYMER CONJUGATES FOR PROLONGED LOCAL ANESTHESIA THE CHILDREN'S MEDICAL CENTER CORPORATION 2025-06-19 US disclosed
US-5041653-A Antitumor agents SRI INTERNATIONAL (US) 1991-08-20 US disclosed
US-5032617-A Antitumor agents SRI INTERNATIONAL (US) 1991-07-16 US disclosed
WO-1986006628-A1 BENZAMIDE AND NICOTINAMIDE RADIOSENSITIZERS SRI INTERNATIONAL (US) 1986-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 RECQL 3024/4885TUBB4A 1516/4885TUBB 1455/4885
US-20250195671-A1 COVALENT ANESTHETIC-POLYMER CONJUGATES FOR PROLONGED LOCAL ANESTHESIA TNNC1, TNNT2, TNNI3 RECQL 3224/4885TUBB4A 1604/4885TUBB 681/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A RECQL 3369/4885TUBB4A 1778/4885TUBB 1883/4885
US-20070123531-A1 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases BDKRB1, BDKRB2, LTB4R RECQL 3952/4885TUBB4A 1936/4885TUBB 2132/4885
US-20260027090-A1 Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity CSF1R, CD209, NFATC1 RECQL 4876/4885TUBB4A 2839/4885TUBB 2929/4885
US-20050032868-A1 Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists BDKRB1, BDKRB2, BRS3 RECQL 3114/4885TUBB4A 3139/4885TUBB 3047/4885
US-20030199553-A1 Antidiabetic agents GPR119, IRS1, INSR RECQL 1182/4885TUBB4A 2937/4885TUBB 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.